Scarboro contends these findings should be treated as design information rather than as a sign that patients need more ...

Manufacturers are encouraged to treat resiliency policy as an actionable trend and proactively shape solutions rather than ...

Patrik Florencio | Authors | Pharmaceutical Technology serves as the connection to bio manufacturing and development, featuring regulatory updates and expert industry news.

Access Part 1 of this interview, in which Piervincenzi explains how benchmarking could reward reliable generic drug suppliers ...

Companies showcasing equipment and services at the event include Shilpa Biologicals (Booth 12J33), which is announcing the ...

Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps. When Merck and Moderna's INTerpath-001 trial of ...

Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence. The FDA's September 22 direct final rule, which swaps ...

In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol ...

Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy. In part 2, of a 3-part interview, Ronald T. Piervincenzi, ...

The FDA has approved AbbVie's JUVMO (tavapadon), as the first and only selective D1/D5 receptor agonist for adults with ...

Machine-readable digital standards integrated into LIMS, ELNs, and regulatory platforms reduce transcription risk, streamline ...

Merck will develop, manufacture, and commercialize SPR2015 globally, while SciBrunch retains milestone upside, reflecting premium valuations for differentiated RAS-pathway assets at preclinical entry.